Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iron sucrose/tin protoporphyrin - Renibus Therapeutics

Next Previous
Drug Profile

Iron sucrose/tin protoporphyrin - Renibus Therapeutics

Alternative Names: FeS/SnPP; RBT-1; Stannous protoporphyrin/iron sucrose; Tin-protoporphyrin/iron-sucrose

Latest Information Update: 01 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Renibus Therapeutics
  • Class Antianaemics; Heavy metals; Urologics
  • Mechanism of Action Decyclizing heme oxygenase inhibitors; Interleukin 10 stimulants; Iron replacements; NF-E2-related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute kidney injury
  • No development reported Renal failure

Most Recent Events

  • 24 Apr 2025 Renibus Therapeutics completes enrolment in its phase-III clinical trials for Acute kidney injury (Prevention) in Canada and the USA (IV) (NCT06021457)
  • 26 Oct 2023 Phase-III clinical trials in Acute kidney injury (Prevention) in Canada (IV) (NCT06021457)
  • 17 Oct 2023 Phase-III clinical trials in Acute kidney injury (Prevention) in USA (IV) (NCT06021457)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top